undamentalytics Newsletter
Sign in

Biocardia, Inc. (BCDA) stock

Add to watchlist

Add holding +

NASDAQ: BCDA Nasdaq Biotechnology Next results ~November 11, 2026

Biocardia, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling34 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds10 adding, 8 cuttingOf 2 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Biocardia, Inc.'s trailing-twelve-month revenue fell 100.0% year on year, with a free-cash-flow margin of -266000.0%.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 32% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Biocardia, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 100.0% over the last 12 months.
  • Loss-making. Operating margin is -281733.3%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 279509.2 points on a year ago.
  • Burning cash. Free cash flow was -266000.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 23566.7% of revenue: a real cost that cash-flow figures leave out.

Latest results: FY2025 Q4

Filed March 24, 2026
Earnings per share
-$0.13 against an average estimate of -$0.19: beat by 31.6%
Share reaction
0.0% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500

Biocardia's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+4.7%
  • 1 week0.0%
  • 1 month-13.5%
  • This year-28.0%
  • 1 year-35.7%
  • 5 years-97.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$0
Operating margin
-281733.3%
Net margin
-279700.0%

Growth

Revenue growth
−100.0%
Change in growth rate
+0.0 pts

Earnings

Last results
August 12, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Announcement
  6. Announcement
  7. Announcement
  8. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Biocardia, Inc. valuation models and calculator

No model value for Biocardia, Inc. at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

24 /100

Weak moat

How hard Biocardia's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -163.9% of total assets over 10 years.

  • Pricing power 9 / 20

    Gross margin has been a median 49.6%, moving by 53.8 percentage points (standard deviation) across 5 years.

  • Durability 10 / 20

    Operating margin has been a median -2327.4%; its worst year was -281733.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 9 years, at a median -1889.1% of revenue.

  • Discipline 10 / 20

    The diluted share count fell 99.1% over five years; stock-based pay has been a median 355.3% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (29 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.71 +42% — 0%
Next −$0.58 +18% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is 0.0% on 90 days ago. In the last 30 days, 1 analyst raised Biocardia, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Biocardia, Inc., last 90 days
−$0.80 −$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.71 Current fiscal year, 60 days ago: −$0.76 Current fiscal year, 30 days ago: −$0.76 Current fiscal year, 7 days ago: −$0.76 Current fiscal year, Now: −$0.71 −$0.71 Next fiscal year, 90 days ago: −$0.56 Next fiscal year, 60 days ago: −$0.60 Next fiscal year, 30 days ago: −$0.60 Next fiscal year, 7 days ago: −$0.60 Next fiscal year, Now: −$0.58 −$0.58

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.71−$0.56
60 days ago −$0.76−$0.60
30 days ago −$0.76−$0.60
7 days ago −$0.76−$0.60
Now −$0.71−$0.58

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.19 −$0.13 +31.6%
Mar 2026 −$0.17 −$0.21 −23.5%
Dec 2025 −$0.20 −$0.06 +70.0%
Sept 2025 −$0.25 −$0.24 +4.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026
Buy2100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202622

Counts of recommendations published by analysts covering Biocardia, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.1%
of tradable shares
Days to cover
2.11
at average volume
Short interest, 1 month
−21%
to October 15, 2026
Held by institutions
15%
of shares
Held by insiders
17.9%
of shares
Employees
17
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BCDA−44%+8%−68%−78%−43%−28%
Industry peers (median)−35%−57%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BCDA33%42%42%33%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BCDA−67%−55%−87%−82%−65%−46%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from January 4, 2017 to July 29, 2026. Getting back needed a 248160% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.77 – $1.47
From 52-week high
−38.8%
vs 50-day average
−14.1%
vs 200-day average
−16.2%
Volatility (1 year)
67%
Beta vs S&P 500
0.48

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±5.5%
After a week
6 up, 6 down
typical move ±21.9%
After a month
5 up, 7 down
typical move ±19.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 0.0% +0.9% +6.5% +16.1%
May 15, 2026 −17.4% −1.3% −11.9% −20.2%
March 24, 2026 0.0% +0.2% +0.8% −2.5%
November 12, 2025 −5.3% −1.6% −0.8% +9.0%
August 11, 2025 −2.8% +0.9% +5.0% +18.4%
May 14, 2025 −15.3% +0.6% −31.4% −20.4%
March 26, 2025 +1.9% −1.5% −13.7% −25.1%
November 13, 2024 −15.8% −0.6% −17.1% −13.3%
August 13, 2024 +2.4% +2.0% +31.6% +11.9%
May 14, 2024 +2.6% +1.7% +5.1% −37.6%
March 27, 2024 −2.4% +0.8% −7.1% −9.5%
November 8, 2023 0.0% −0.7% +131.7% +53.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Biocardia, Inc.
$0 $500K $1M $1.5M FY23 Q1 FY23 Q4 FY24 Q3 FY25 Q4 Revenue (TTM), FY23 Q1: $1.4M Revenue (TTM), FY23 Q2: $425K Revenue (TTM), FY23 Q3: $570K Revenue (TTM), FY23 Q4: $477K Revenue (TTM), FY24 Q1: $468K Revenue (TTM), FY24 Q2: $428K Revenue (TTM), FY24 Q3: $71K Revenue (TTM), FY24 Q4: $58K Revenue (TTM), FY25 Q1: $3K Revenue (TTM), FY25 Q2: $0 Revenue (TTM), FY25 Q3: $0 Revenue (TTM), FY25 Q4: $0 $0

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY23 Q1 $1.4M
FY23 Q2 $425K
FY23 Q3 $570K
FY23 Q4 $477K
FY24 Q1 $468K
FY24 Q2 $428K
FY24 Q3 $71K
FY24 Q4 $58K
FY25 Q1 $3K
FY25 Q2 $0
FY25 Q3 $0
FY25 Q4 $0
Revenue growth, TTM YoY Biocardia, Inc.
-100% -50% 0% 50% FY23 Q1 FY23 Q4 FY24 Q3 FY25 Q4 Revenue growth, TTM YoY, FY23 Q1: 31.8% Revenue growth, TTM YoY, FY23 Q2: -78.0% Revenue growth, TTM YoY, FY23 Q3: -57.0% Revenue growth, TTM YoY, FY23 Q4: -64.7% Revenue growth, TTM YoY, FY24 Q1: -65.5% Revenue growth, TTM YoY, FY24 Q2: 0.7% Revenue growth, TTM YoY, FY24 Q3: -87.5% Revenue growth, TTM YoY, FY24 Q4: -87.8% Revenue growth, TTM YoY, FY25 Q1: -99.4% Revenue growth, TTM YoY, FY25 Q2: -100.0% Revenue growth, TTM YoY, FY25 Q3: -100.0% Revenue growth, TTM YoY, FY25 Q4: -100.0% -100.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q1 31.8%
FY23 Q2 -78.0%
FY23 Q3 -57.0%
FY23 Q4 -64.7%
FY24 Q1 -65.5%
FY24 Q2 0.7%
FY24 Q3 -87.5%
FY24 Q4 -87.8%
FY25 Q1 -99.4%
FY25 Q2 -100.0%
FY25 Q3 -100.0%
FY25 Q4 -100.0%
Operating margin (TTM) Biocardia, Inc.
-300000% -200000% -100000% 0% FY22 Q2 FY23 Q1 FY23 Q4 FY25 Q1 Operating margin (TTM), FY22 Q2: -620.1% Operating margin (TTM), FY22 Q3: -931.6% Operating margin (TTM), FY22 Q4: -880.3% Operating margin (TTM), FY23 Q1: -891.2% Operating margin (TTM), FY23 Q2: -3068.2% Operating margin (TTM), FY23 Q3: -2206.7% Operating margin (TTM), FY23 Q4: -2441.1% Operating margin (TTM), FY24 Q1: -2224.1% Operating margin (TTM), FY24 Q2: -2010.7% Operating margin (TTM), FY24 Q3: -10935.2% Operating margin (TTM), FY24 Q4: -13794.8% Operating margin (TTM), FY25 Q1: -281733.3% -281733.3%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY22 Q2 -620.1%
FY22 Q3 -931.6%
FY22 Q4 -880.3%
FY23 Q1 -891.2%
FY23 Q2 -3068.2%
FY23 Q3 -2206.7%
FY23 Q4 -2441.1%
FY24 Q1 -2224.1%
FY24 Q2 -2010.7%
FY24 Q3 -10935.2%
FY24 Q4 -13794.8%
FY25 Q1 -281733.3%
FCF margin (TTM) Biocardia, Inc.
-300000% -200000% -100000% 0% FY22 Q2 FY23 Q1 FY23 Q4 FY25 Q1 FCF margin (TTM), FY22 Q2: -583.8% FCF margin (TTM), FY22 Q3: -803.6% FCF margin (TTM), FY22 Q4: -786.3% FCF margin (TTM), FY23 Q1: -756.6% FCF margin (TTM), FY23 Q2: -2527.5% FCF margin (TTM), FY23 Q3: -1953.3% FCF margin (TTM), FY23 Q4: -2093.5% FCF margin (TTM), FY24 Q1: -1911.5% FCF margin (TTM), FY24 Q2: -1660.7% FCF margin (TTM), FY24 Q3: -10294.4% FCF margin (TTM), FY24 Q4: -13606.9% FCF margin (TTM), FY25 Q1: -266000.0% -266000.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY22 Q2 -583.8%
FY22 Q3 -803.6%
FY22 Q4 -786.3%
FY23 Q1 -756.6%
FY23 Q2 -2527.5%
FY23 Q3 -1953.3%
FY23 Q4 -2093.5%
FY24 Q1 -1911.5%
FY24 Q2 -1660.7%
FY24 Q3 -10294.4%
FY24 Q4 -13606.9%
FY25 Q1 -266000.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Dec 2010 2011 Dec 2011 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 0 0 1 1 0 1 1 0 1 1 0 0 0
Gross profit 0 0 — −0 −0 0 0 0 1 — — — —
EBITDA 0 −1 −5 −8 −12 −14 −14 −15 −13 −12 −12 −8 −8
Operating income −1 −1 −5 −8 −12 −14 −14 −16 −13 −12 −12 −8 −8
Net income −12 10 −7 −10 −12 −14 −15 −15 −13 −12 −12 −8 −8
Diluted EPS −$9.00 $0.48 −$51.48 −$18.45 −$21.75 −$24.60 −$1.30 −$0.74 −$0.38 — — — —
Growth (year on year)
Revenue — — +>999% −36.3% −16.8% +30.5% +13.6% −79.6% +600.0% +33.2% −64.7% −87.8% −100.0%
EBITDA — −260.9% — — — — — — — — — — —
Net income — — −169.3% — — — — — — — — — —
Diluted EPS — — <−999% — — — — — — — — — —
Margins
Gross margin — 100.0% — −29.5% −44.1% 17.3% 49.6% 97.2% 100.0% — — — —
EBITDA margin — <−999% −593.1% <−999% <−999% <−999% <−999% <−999% <−999% −874.2% <−999% <−999% —
Operating margin — <−999% −598.3% <−999% <−999% <−999% <−999% <−999% <−999% −880.3% <−999% <−999% —
Net margin — >999% −740.8% <−999% <−999% <−999% <−999% <−999% <−999% −880.7% <−999% <−999% —
Free-cash-flow margin — <−999% −790.7% — <−999% <−999% <−999% <−999% <−999% −786.3% <−999% <−999% —
Cash flow
Cash from operations −4 −3 −7 −6 −9 −11 −9 −12 −10 −11 −10 −8 −7
Capital spending 1 0 0 — 0 0 0 0 0 0 0 0 0
Free cash flow −5 −3 −7 — −9 −11 −10 −12 −10 −11 −10 −8 −7
Stock-based pay 0 0 0 1 3 3 3 3 2 1 1 1 0
Free cash flow after stock pay −5 −3 −7 — −12 −14 −12 −15 −12 −12 −11 −9 −8
Balance sheet
Cash 0 13 4 21 13 5 6 21 13 7 1 2 2
Total debt 0 0 6 0 0 0 0 1 0 0 0 0 0
Net debt (negative = net cash) −0 −13 2 −21 −13 −5 −6 −21 −13 −7 −1 −2 −2
Diluted shares 1m 1m 1m — — — — 1m 2m 2m 3m 3m 7m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

R&D spending
155866.7%
of revenue
Sales & admin spending
125966.7%
of revenue

Who owns it

Funds buying and selling
Reported value
$1.6M
Institutions reporting
21
Shares held vs prior quarter
▲ 94.2%
Positions opened / closed
6 / 5

Top buyers and sellers, Q2 2026: 10 institutions bought and 8 sold ; the biggest buyer was Citigroup Inc (+398K shares) and the biggest seller Citadel Advisors LLC (−40K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Citigroup Inc $493,017 398K 29.9% New
Cm Management, LLC $372,000 300K 22.6% ▲ 130.8%
Vanguard Capital Management LLC $154,493 125K 9.4% 0.0%
Pingora Partners LLC $149,274 120K 9.1% ▲ 236.8%
UBS Group AG $96,248 78K 5.8% New
Geode Capital Management, LLC $82,662 67K 5.0% ▼ 29.3%
Vanguard Fiduciary Trust Co $82,175 66K 5.0% 0.0%
Susquehanna International Group, LLP $48,123 39K 2.9% 0.0%
Brown Advisory Inc $44,067 36K 2.7% 0.0%
Commonwealth Equity Services, LLC $28,990 23K 1.8% ▲ 27.9%
Citadel Advisors LLC $28,465 23K 1.7% ▼ 63.8%
Stonex Group Inc. $24,825 20K 1.5% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Biocardia, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $169,641 34 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $169,641 net buying
Insider Date Trade Shares Price Value
Altman Peter President and CEO October 16, 2026 Buy 300 $0.95 $285
Altman Peter President and CEO October 15, 2026 Buy 200 $0.95 $190
Altman Peter President and CEO September 29, 2026 Buy 1,000 $1.03 $1,030
Altman Peter President and CEO September 23, 2026 Buy 1,900 $1.05 $1,995
Altman Peter President and CEO September 3, 2026 Buy 800 $1.09 $872
Altman Peter President and CEO August 17, 2026 Buy 5,400 $0.93 $5,022
Altman Peter President and CEO August 13, 2026 Buy 1,900 $0.92 $1,748
Altman Peter President and CEO July 29, 2026 Buy 5,000 $0.78 $3,900
Altman Peter President and CEO July 17, 2026 Buy 500 $0.83 $415
Altman Peter President and CEO July 15, 2026 Buy 1,500 $0.86 $1,290
Altman Peter President and CEO July 14, 2026 Buy 2,800 $0.88 $2,464
Altman Peter President and CEO July 10, 2026 Buy 1,000 $0.94 $940

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 15, 2026
  • March 24, 2026
  • November 12, 2025
  • August 11, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Biocardia, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Biocardia, Inc. in brief

What does Biocardia, Inc. do?
Biocardia, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Biocardia, Inc.'s stock ticker?
Biocardia, Inc. trades under the ticker BCDA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Biocardia, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Biocardia, Inc. reported revenue of $0, 100.0% lower than a year earlier, according to its SEC filings.
What is Biocardia, Inc.'s free cash flow?
Biocardia, Inc.'s free-cash-flow margin is -266000.0% of revenue over the trailing twelve months.
Who are Biocardia, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Citigroup Inc, Cm Management, LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Biocardia, Inc.'s market cap?
On December 31, 2025, Biocardia, Inc.'s market capitalisation was about $8.3M and net debt of -$2.5M. Market figures come from third-party market data and may be delayed.
Are insiders buying or selling Biocardia, Inc. stock?
Over the last 12 months, Biocardia, Inc.'s directors and officers reported 34 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Biocardia, Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Biocardia, Inc. announces its own schedule.